Cardiac phenotype of Duchenne Muscular Dystrophy: Insights from cellular studies

Journal of Molecular and Cellular Cardiology

Volumn 58, Issue 1, 2013, Pages 217-224

  Shirokova, Natalia ^a   Niggli, Ernst ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Ca2+ signals; Dystrophic cardiomyopathy; Excitation contraction coupling; Ryanodine receptor

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION; MYOGENIC DIFFERENTIATION FACTOR D; MYOGENIC FACTOR; RYANODINE RECEPTOR; SODIUM CALCIUM EXCHANGE PROTEIN; STRETCH ACTIVATED CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; UTROPHIN; VANILLOID RECEPTOR 2;

CARDIAC DYSTROPHY; CLINICAL FEATURE; DEGRADATION KINETICS; DISEASE ASSOCIATION; DMD GENE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVITY; ENZYME REGULATION; GENE; GENE AMPLIFICATION; GENE MUTATION; HEART DISEASE; HEART FUNCTION; HUMAN; MEMBRANE RUPTURE; NITROSATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, DILATED; DYSTROPHIN; HEART FAILURE; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCYTES, CARDIAC;

EID: 84876312106     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.12.009     Document Type: Review

References (76)

1. Clarac F., Massion J., Smith A.M. Duchenne, Charcot and Babinski, three neurologists of La Salpetrière Hospital, and their contribution to concepts of the central organization of motor synergy. J Physiol Paris 2009, 103:361-376.
2. Finsterer J., Stöllberger C. The heart in human dystrophinopathies. Cardiology 2003, 99:1-19.
3. Hermans M.C.E., Pinto Y.M., Merkies I.S.J., de Die-Smulders C.E.M., Crijns H.J.G.M., Faber C.G. Hereditary muscular dystrophies and the heart. Neuromuscul Disord 2010, 20:479-492.
4. Yilmaz A., Sechtem U. Cardiac involvement in muscular dystrophy: advances in diagnosis and therapy. Heart 2012, 98:420-429.
5. Aartsma-Rus A., Van Deutekom J.C.T., Fokkema I.F., Van Ommen G.-J.B., Dunnen Den J.T. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006, 34:135-144.
6. Hoffman E.P., Brown R.H., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
7. Ervasti J.M., Campbell K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993, 122:809-823.
8. Kaprielian R.R., Stevenson S., Rothery S.M., Cullen M.J., Severs N.J. Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. Circulation 2000, 101:2586-2594.
9. Kaprielian R.R., Severs N.J. Dystrophin and the cardiomyocyte membrane cytoskeleton in the healthy and failing heart. Heart Fail Rev 2000, 5:221-238.
10. Yasuda S., Townsend D., Michele D.E., Favre E.G., Day S.M., Metzger J.M. Dystrophic heart failure blocked by membrane sealant poloxamer. Nat Cell Biol 2005, 436:1025-1029.
11. 2+ influx into dystrophic mdx cardiomyocytes. Cell Calcium 2009, 46:114-121.
12. Van Erp C., Loch D., Laws N., Trebbin A., Hoey A.J. Timeline of cardiac dystrophy in 3-18-month-old MDX mice. Muscle Nerve 2010, 42:504-513.
13. Hutter OF, Burton F.L., Bovell D.L. Mechanical properties of normal and mdx mouse sarcolemma: bearing on function of dystrophin. J Muscle Res Cell Motil 1991, 12:585-589.
14. 2+ loading reduces the tensile strength of sarcolemmal vesicles shed from rabbit muscle. J Physiol 1996, 493:199-209.
15. Im W.B., Phelps S.F., Copen E.H., Adams E.G., Slightom J.L., Chamberlain J.S. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 1996, 5:1149-1153.
16. Quinlan J.G., Hahn H.S., Wong B.L., Lorenz J.N., Wenisch A.S., Levin L.S. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 2004, 14:491-496.
17. Danialou G., Comtois A.S., Dudley R., Karpati G., Vincent G., Rosiers Des C., et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 2001, 15:1655-1657.
18. Zhang W., Hove ten M., Schneider J.E., Stuckey D.J., Sebag-Montefiore L., Bia B.L., et al. Abnormal cardiac morphology, function and energy metabolism in the dystrophic mdx mouse: An MRI and MRS study. J Mol Cell Cardiol 2008, 45:754-760.
19. Bia B.L., Cassidy P.J., Young M.E., Rafael J.A., Leighton B., Davies K.E., et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 1999, 31:1857-1862.
20. Chu V., Otero J.M., Lopez O., Sullivan M.F., Morgan J.P., Amende I., et al. Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy. Muscle Nerve 2002, 26:513-519.
21. Love D.R., Hill D.F., Dickson G., Spurr N.K., Byth B.C., Marsden R.F., et al. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 1989, 339:55-58.
22. Deconinck A.E., Rafael J.A., Skinner J.A., Brown S.C., Potter A.C., Metzinger L., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997, 90:717-727.
23. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., Sanes J.R. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 1997, 90:729-738.
24. Janssen P.M.L. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 2005, 289:H2373-H2378.
25. Megeney L.A., Kablar B., Perry R.L., Ying C., May L., Rudnicki M.A. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci U S A 1999, 96:220-225.
26. Shelton G.D., Engvall E. Canine and feline models of human inherited muscle diseases. Neuromuscul Disord 2005, 15:127-138.
27. Williams I.A., Allen D.G. Intracellular calcium handling in ventricular myocytes from mdx mice. Am J Physiol Heart Circ Physiol 2006, 292:H846-H855.
28. 2+ signalling and reactive oxygen species-generating pathways. Cardiovasc Res 2007, 77:766-773.
29. Poláková E., Shirokova N. Abnormal sodium handling and mitochondrial metabolism in cardiac dystrophy. Biophys J 2011, 100:81a. [abstract].
30. Prosser B.L., Ward C.W., Lederer W.J. X-ROS signaling: rapid mechano-chemo transduction in heart. Science 2011, 333:1440-1445.
31. Ullrich N.D., Fanchaouy M., Gusev K., Shirokova N., Niggli E. Hypersensitivity of excitation-contraction coupling in dystrophic cardiomyocytes. Am J Physiol Heart Circ Physiol 2009, 297:H1992-H2003.
32. Williams I.A., Allen D.G. The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 2007, 293:H1969-H1977.
33. Bridges L.R.L. The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice. J Neurol Sci 1986, 72:147-157.
34. Millay D.P., Sargent M.A., Osinska H., Baines C.P., Barton E.R., Vuagniaux G., et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008, 14:442-447.
35. Deconinck N., Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7.
36. Franco A., Lansman J.B. Calcium entry through stretch-inactivated ion channels in mdx myotubes. Nature 1990, 344:670-673.
37. Allen D.G. Mechanisms of stretch-induced muscle damage in normal and dystrophic muscle: role of ionic changes. J Physiol 2005, 567:723-735.
38. 2+ channel by the actin-binding proteins alpha-actinin and dystrophin. Am J Physiol Cell Physiol 2002, 282:C1502-C1511.
39. Gervasio O.L., Whitehead N.P., Yeung E.W., Phillips W.D., Allen D.G. TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy. J Cell Sci 2008, 121:2246-2255.
40. Zanou N., Iwata Y., Schakman O., Lebacq J., Wakabayashi S., Gailly P. Essential role of TRPV2 ion channel in the sensitivity of dystrophic muscle to eccentric contractions. FEBS Lett 2009, 583:3600-3604.
41. Straub V., Rafael J.A., Chamberlain J.S., Campbell K.P. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol 1997, 139:375-385.
42. Wu G., Majewski J., Ege C., Kjaer K., Weygand M., Lee K. Lipid corralling and poloxamer squeeze-out in membranes. Phys Rev Lett 2000, 93:028101.
43. Maroto R., Raso A., Wood T.G., Kurosky A., Martinac B., Hamill O.P. TRPC1 forms the stretch-activated cation channel in vertebrate cells. Nat Cell Biol 2005, 7:179-185.
44. Dyachenko V., Husse B., Rueckschloss U., Isenberg G. Mechanical deformation of ventricular myocytes modulates both TRPC6 and Kir2.3 channels. Cell Calcium 2009, 45:38-54.
45. Ward M.-L., Williams I.A., Chu Y., Cooper P.J., Ju Y.-K., Allen D.G. Stretch-activated channels in the heart: contributions to length-dependence and to cardiomyopathy. Prog Biophys Mol Biol 2008, 97:232-249.
46. Galbiati F., Volonte D., Chu J.B., Li M., Fine S.W., Fu M., et al. Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc Natl Acad Sci U S A 2000, 97:9689-9694.
47. Aravamudan B. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype. Hum Mol Genet 2003, 12:2777-2788.
48. Millay D.P., Goonasekera S.A., Sargent M.A., Maillet M., Aronow B.J., Molkentin J.D. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc Natl Acad Sci U S A 2009, 106:19023-19028.
49. 2+ entry and cytoskeletal damage following eccentric contractions in mouse skeletal muscle. J Appl Physiol 2012, 112:2077-2086.
50. Beyder A., Strege P.R., Reyes S., Bernard C.E., Terzic A., Makielski J., et al. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel NaV1.5: a novel mechanism of drug action. Circulation 2012, 125:2698-2706.
51. Petitprez S., Zmoos A.F., Ogrodnik J., Balse E., Raad N., El-Haou S., et al. SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes. Circ Res 2011, 108:294-304.
52. Song M.Y., Makino A., Yuan J.X.J. Role of reactive oxygen species and redox in regulating the function of transient receptor potential channels. Antioxid Redox Signal 2011, 15:1549-1565.
53. Fauconnier J., Thireau J., Reiken S., Cassan C., Richard S., Matecki S., et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010, 107:1559-1564.
54. Wehrens X.H.T., Lehnart S.E., Reiken S., Vest J.A., Wronska A., Marks A.R. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci U S A 2006, 103:511-518.
55. Hasenfuss G., Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 2002, 34:951-969.
56. Meissner G. Regulation of Ryanodine receptor ion channels through posttranslational modifications. Curr Top Membr 2010, 66:91-113.
57. Wehrens X.H.T., Lehnart S.E., Marks A.R. Intracellular calcium release and cardiac disease. Annu Rev Physiol 2005, 67:69-98.
58. 2+ signaling and EC-coupling. Biochim Biophys Acta 2012, 10.1016/j.bbamcr.2012.08.016.
59. Venetucci L.A., Trafford A.W., Eisner D.A. Increasing ryanodine receptor openprobability alone does not produce arrhythmogenic calcium waves: threshold sarcoplasmic reticulum calcium content is required. Circ Res 2007, 100:105-111.
60. Kyrychenko S, Poláková E, Kang C, Pocsai K, Ullrich ND, Niggli E, Shirokova N. Hierarchical accumulation of RyR post-translational modifications drives disease progression in dystrophic cardiomyopathy. Cardiovascular Research in press. http://dx.doi.org/10.1016/j.yjmcc.2012.12.00.
61. Hidalgo C., Donoso P. Crosstalk between calcium and redox signaling: from molecular mechanisms to health implications. Antioxid Redox Signal 2008, 10:1275-1312.
62. Whitehead N.P., Yeung E.W., Allen D.G. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006, 33:657-662.
63. 2+ signals in stressed mdx dystrophic skeletal muscle fibers. Pflugers Arch 2009, 458:915-928.
64. Rando T.A. Role of nitric oxide in the pathogenesis of muscular dystrophies: a "two hit" hypothesis of the cause of muscle necrosis. Microsc Res Tech 2001, 55:223-235.
65. Jiang F., Zhang Y., Dusting G.J. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 2011, 63:218-242.
66. 2+ signals produced by osmotic stress in mouse skeletal muscle fibres. J Physiol 2008, 586:197-210.
67. 2+ signals contributes to angiotensin II-induced hypertrophy in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 2012, 302:H901-H909.
68. Zhou C. Angiotensin II and stretch activate NADPH oxidase to destabilize cardiac Kv4.3 channel mRNA. Circ Res 2006, 98:1040-1047.
69. Bellinger A.M., Reiken S., Carlson C., Mongillo M., Liu X., Rothman L., et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med 2009, 15:325-330.
70. Su J.B., Cazorla O., Blot S., Blanchard-Gutton N., Mou Y.A., Barthelemy I., et al. Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. Cardiovasc Res 2012, 95:86-96.
71. Hammond J., Balligand J.-L. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. J Mol Cell Cardiol 2012, 52:330-340.
72. Khairallah M., Khairallah R.J., Young M.E., Allen B.G., Gillis M.A., Danialou G., et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci U S A 2008, 105:7028-7033.
73. George C.H., Jundi H., Thomas N.L., Scoote M., Walters N., Williams A.J., et al. Ryanodine receptor regulation by intramolecular interaction between cytoplasmic and transmembrane domains. Mol Biol Cell 2004, 15:2627-2638.
74. Sarma S., Li N., van Oort R.J., Reynolds C., Skapura D.G., Wehrens X.H.T. Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy. Proc Natl Acad Sci U S A 2010, 107:13165-13170.
75. Erickson J.R., Joiner M.-L.A., Guan X., Kutschke W., Yang J., Oddis C.V., et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008, 133:462-474.
76. Ather S., Wang W., Wang Q., Li N., Anderson M.E., Wehrens X.H.T. Inhibition of CaMKII Phosphorylation of RyR2 Prevents Inducible Ventricular Arrhythmias in Mice with Duchenne Muscular Dystrophy. Heart Rhythm 2012, http://dx.doi.org/10.1016/j.hrthm.2012.12.016 [pii: S1547-5271(12)01450-6. Epub ahead of print].